MJardin Group Announces Medical Cannabis Research Investment in Spain

Collaboration with Salamanca University and the Institute of
Neuroscience of Castilla y León to Study the Benefits of Cannabinoids on
Epilepsy and Schizophrenia

DENVER–(BUSINESS WIRE)–MJardin Group, Inc. (“MJardin” or the “Company”)
(CSE:MJAR), a leader in cannabis management, today announced its first
medical cannabis research investment to fund two studies on the benefits
of cannabinoids on epilepsy and schizophrenia.

Beginning in the first quarter of 2019, the studies will be conducted in
Salamanca, Spain for a period of one year, in collaboration with
Salamanca University and the Institute of Neuroscience of Castilla y
León – two of the leading institutions globally for the scientific
research of the nervous system and its diseases.

The research will focus on the effects of cannabidiol (CBD) on epilepsy
and schizophrenia and will be led by Dr. Dolores López, Ph.D. and Dr.
Manuel S. Malmierca, Ph.D., M.D., both of whom are experts in
neurodegenerative diseases and world renowned for their research on the
effect of cannabinoids on neurological health

Christine Halef, BSc Pharm, RPh., SVP, Medical Strategy for MJardin, and
Dr. Ashley Masri, ND, Medical Director for MJardin, will oversee the
research for MJardin.

Halef founded AtlantiCann Medical Inc. and her background as a
pharmacist provides a patient-focused perspective on providing
alternative treatment options to conditions that commonly afflict
communities across Canada.

Dr. Masri holds a postgraduate degree in Naturopathic Medicine from the
Canadian College of Naturopathic Medicine and leverages her scientific
background and experience working with natural health products in
patient care to coordinate MJardin’s medical research efforts.

“There is a lot of work to be done from pre-clinical to clinical trials,
to better understand the medical benefits of cannabis on serious
neurological disorders such as epilepsy and schizophrenia,” said Dr.
Masri. “Spain is a recognized hub for medical cannabis research and we
are very pleased to have the opportunity to collaborate with Salamanca
University and the Institute of Neuroscience of Castilla y León to
address this research gap and identify opportunities to improve the
lives of millions globally.”

Dr. Dolores López, Research Full Professor at the University of
Salamanca and Director of the Audiomotor Disorder’s Lab at the
Neuroscience Institute of Castilla y Leon, commented, “The collaboration
agreement between MJardin and the University of Salamanca opens up a
great opportunity to transfer university knowledge to society, setting
up the possibility of new treatments for epilepsy and schizophrenia.
This research project will provide guidance on safety, dosage and
efficacy of cannabidiol-based drugs, and will allow us to increase the
visibility of our research within the scientific community.”

MJardin will leverage the research to guide the focus of the Company’s
medical cannabis division, including the development of new products to
treat a range of neurological conditions and disorders. Following
completion of the studies, MJardin anticipates engaging with the
appropriate regulatory bodies to begin research and testing of its
products in Canada.

As the leaders of MJardin’s medical cannabis division, Halef and Dr.
Masri will focus on developing strategic R&D partnerships with reputable
research organizations to ensure reliability and safety of medicinal
products to both physicians and patients.

“We are proud to provide financial support for this critical research
while also attracting and convening a global coalition of experts to
advance medical cannabis research, deepen the industry’s understanding
of medical cannabis, ensure safe and effective patient care, and grow
MJardin’s medical division,” added Rishi Gautam, Chairman and Chief
Executive Officer of MJardin.

About MJardin Group

MJardin is a global cannabis management platform with extensive
experience in cultivation, processing, distribution and retail. For over
10 years, MJardin has refined cultivation methodologies, developed state
of the art facilities and implemented vertical integration for and on
behalf of license owners. As a well-capitalized organization, MJardin
continues to pursue strategic expansion and M&A opportunities across
global legal cannabis markets. MJardin is based in Denver Colorado, with
offices in Toronto, Canada and Barcelona, Spain. For more information,
please visit www.mjardin.com.

The CSE has not in any way passed upon the merits of and has neither
approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell or a
solicitation of an offer to sell any of the securities in the United
States. The securities have not been and will not be registered under
the United States Securities Act of 1933, as amended (the “U.S.
Securities Act”) or any state securities laws and may not be offered
or sold within the United States or to U.S. Persons unless registered
under the U.S. Securities Act and applicable state securities laws or an
exemption from such registration is available.

Forward-Looking Information

This news release contains forward-looking information based on
current expectations. Statements about, among other things, future
developments and the business and operations of MJardin, the medical
studies discussed in this press release, the growth of or global
footprint and our intentions to leverage our scale for continued organic
growth and to pursue strategic investments are all forward-looking
information. These statements should not be read as guarantees of
future performance or results. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results, performance or achievements to be materially different from
those implied by such statements. Such factors include, but are
not limited to: our ability to identify and pursue growth, financing and
other strategic objectives, and the regulatory and economic environments
in the jurisdictions we operate or intend to operate or investment in.
Although such statements are based on management’s reasonable
assumptions at the date such statements are made, there can be no
assurance that the proposed acquisition will occur and that such
forward-looking information will prove to be accurate, as actual results
and future events could differ materially from those anticipated in such
forward-looking information. Accordingly, readers should not
place undue reliance on the forward-looking information. MJardin
assumes no responsibility to update or revise forward-looking
information to reflect new events or circumstances unless required by
applicable law.

Contacts

Media:
Cory Ziskind
ICR
646-277-1232
cory.ziskind@icrinc.com

Investors:
Ali Mahdavi
Capital Markets & Investor
Relations
416-962-3300
Ali.mahdavi@mjardin.com
or
Frank
Knuettel II, 720-613-4019
Chief Strategy Officer
Frank.Knuettel@MJardin.com